Introduction
============

Otitis externa (OE), an infection of the external auditory canal, is common worldwide with a prevalence of 10%. The exact incidence is unknown. The acute form of the disease affects 4 in 1,000 persons and the chronic form affects 3--5% of the population of the United States annually. The clinical picture of OE consists of redness, pain, itching, secretion, along with conductive hearing loss, and even dizziness at times. Otitis externa caused by *Pseudomonas aeruginosa* may turn malignant and progress to pseudomonal temporal bone osteomyelitis. It is more common in swimmers, humid environments, and people with hearing aids, absence of ear wax, narrow ear canals, and mechanical trauma. [@JR0520-1] [@JR0520-2] [@JR0520-3]

The empirical therapy should be considered for successful treatment of the disease. Wide-spectrum antimicrobial drugs (AMD), which are active against the most possible pathogens, particularly *P.aeruginosa* , antipseudomonal cephalosporins (ceftazidime, cefepime), and fluoroquinolones (ciprofloxacin), should be prescribed as soon as possible.

Ciprofloxacin, is a drug of choice for treating severe otitis externa. Due to its better absorption, wide distribution, and broad spectrum of activity against gram negative and gram positive pathogens, severe infections can be treated orally. This can reduce the number of hospitalizations required for parenteral therapy and patients can be discharged from the hospital earlier. [@JR0520-4]

The current gold-standard treatment in uncomplicated cases consists of appropriate analgesia, topical antibiotics with or without topical steroids. However, severe or resistant cases such as patients who are systemically unwell, immunosuppressed, suffering from complications, or have canal stenosis are treated by systemic antibiotics. [@JR0520-5] Moreover, Otitis externa is accompanied by severe diffuse edema of the cartilaginous part of the external auditory canal skin, which makes the use of topical antibacterial drugs challenging.

Ciprofloxacin exerts bactericidal effect on gram-negative microorganisms not only during division but also at resting stage. This property of the drug ensures its higher clinical efficacy as compared with penicillins, cephalosporins, and aminoglycosides which affect only multiplying bacteria. It is also considered as the very potent antibiotic affecting problematic microorganisms - *P. aeruginosa* (including multi-drug resistant strains) and *Staphylococcus aureus* (including some methicillin-resistant strains).

Very few studies have been conducted in the primary care environment over the use of topical or oral antibiotics therapy in otitis externa management.

The present study aims to investigate and evaluate, in clinical practice, clinical and microbiological efficacy, tolerance, and determination of optimum treatment period with systemically administered ciprofloxacin in the treatment of external bacterial otitis (EBO).

Methods
=======

Participants and Study Design
-----------------------------

This was a Prospective, Phase IV, Open label, Observational Study. The study took place over the period between March 2013 and August 2013 in one of the diagnostic centers in Moscow.

We studied external bacterial otitis (EBO) outpatients who visited the ENT clinic; we collected data from two cohorts of patients: Group 1 - acute external bacterial otitis (AEBO) and Group 2 - exacerbation of chronic EBO group (CEBO).

We conducted the study in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP). All patients provided signed informed consent prior to the start of the study in accordance with local regulations and standards of Bioethics.

We included in the study patients of both genders (male and female) aged 18 to 65 years with EBO symptoms during the acute stage or during the exacerbation stage of chronic otitis externa. This criteria was regardless of the pathological process, spreading rate, presence of complications, or aggravating factors (prolonged antibiotic, hormonal drugs, cytostatics, radiotherapy of neoplasms, presence of chronic somatic diseases, and secondary immune deficiency caused by these diseases).

We excluded from the study patients with a history of hypersensitivity to ciprofloxacin or any other quinolone agent and those using systemic and/or topical AMDs less than two weeks before visiting the physician.

We also excluded from the study patients with any condition that did not meet the protocol requirement or who, in the opinion of the physician, makes the patient unsuitable for inclusion, were excluded from the study.

Therapeutic Scheme and Dose Assignment
--------------------------------------

In each group, patients received ciprofloxacin (Ciprolet film coated tablets 500mg; Dr. Reddy\'s Laboratory, Hyderabad, India) twice daily in addition to the standard topical EBO treatment (phenazone and lidocaine hydrochloride 1g solution), which is instilled into the external auditory canal of the patient\'s affected ear, either with 5 drops 3 times daily, or every 1.5--2 hours if applying cotton wick. [@JR0520-6] The treatment was administered for 10 days.

Patients also received hyposensitization treatment with or without administration of nonsteroidal anti-inflammatory drugs for analgesia during the whole course of antibacterial therapy of external otitis.

The study drug was given until we achieved clinically significant results but not longer than 10 days.

Assessments
-----------

We evaluated study participants prior to treatment, on the day of treatment initiation (Day 1), and during the treatment visits on Days 1, 3, 5, and 10. The duration of study for each patient in this program was 10 days.

We took a detailed history of all patients and performed aural toilet prior to any examination. Besides common clinical examination and otomicroscopy, patients underwent microscopic and bacteriological investigation of the discharge from external ear canal of the affected ear on the day of visit. We performed otoscopy at every study visit.

***Clinical Assessment and Otoscopic examination*** took place on visit days 1, 3, 5, and 10. We assessed the following clinical parameters: Body temperature, Ear pain, Hearing acuity, Pathological discharge from the ear, Itching of skin, Pain when pressing the hircus, Hyperemia and infiltration of the skin of cartilage part of external ear canal, Narrowing of the lumen of cartilage part of the external ear canal. We rated the clinical parameters as per severity according to 4 categories (Absent, Mild, Moderate, and Severe) by the physician at all clinic visits.

***Antimicrobial Effectiveness*** was determined by bacteriological determinations (ear canal cultures): a smear of secretion from the external auditory canal of the patient\'s affected ear was taken for microscopic and microbiological analysis on the day of presentation before treatment initiation and on Day 10. In all cases, we analyzed the smear microscopy stained by Gram\'s Method to identify gram-positive or gram-negative microbial flora.

Study Endpoints
---------------

We assessed **Clinical Effectiveness** by the proportion of patients who experienced clinical success as assessed by complete resolution of the inflammatory process at the end of therapy in both the groups.

We assessed **Antimicrobial Effectiveness** by the bacteriological eradication at the end of therapy.

The other criteria for of assessment were Subjective General Efficacy Assessment (reported by physician): Pronounced, Satisfactory and Unsatisfactory effect; Subjective General Tolerability Assessment (reported by physician): Good, Satisfactory, and Unsatisfactory; and the percentage of patients with positive dynamics of otitis externa.

We monitored, classified and reported all adverse events (AEs) according to good clinical practice (GCP) standards from the local regulatory authority.

Results
=======

We studied 60 external bacterial otitis (EBO) outpatients, referred to the Otorhinolaryngology clinic. We collected data from two cohorts of patients: Group 1 - acute external bacterial otitis (AEBO) ( *N*  = 30) and Group 2 - exacerbation of chronic EBO group (CEBO) ( *N*  = 30). The 60 were comprised of 24 men and 36 women aged 19 to 60 years (median age 34.7 ± 5.6 years).

The disease onset was associated with water entry into the external auditory canal during swimming. Majority of them had cleaned the external auditory canal using a cotton wick or other means before swimming or immediately after.

The period of disease (exacerbation) was 2 to 5 days prior to the study initiation. The causative microorganisms belonged to both gram positive and gram negative micro flora.

A few patients used antihistamines and non-steroid anti-inflammatory drugs for pain relief during the first 1.5--2 days from the treatment initiation of otitis externa.

Efficacy Analysis
-----------------

### Clinical Effectiveness

We observed good positive dynamics on otoscopy and complete resolution of the inflammatory process in the external auditory canal by the end of therapy.

We present a summary table of signs and symptoms of Otitis Externa at baseline in [Table 1](#TB0520-1){ref-type="table"} .

###### Baseline assessment of signs and symptoms of otitis externa by the physician ( *N*  = 60)

  ----------------------------------------------------------------------------------
                                          Absent    Mild      Moderate   Severe
  --------------------------------------- --------- --------- ---------- -----------
  **Complaints by patients**                                             

  **Ear pain**                                                           

  AEBO (Group 1) ( *N*  = 30)\            0 (0%)    0 (0%)    0 (0%)     30 (100%)
  n (%)                                                                  

  CEBO (Group 2) ( *N*  = 30)\            0 (0%)    0 (0%)    0 (0%)     30 (100%)
  n (%)                                                                  

  **Hearing Impairment**                                                 

  Group 1                                 2 (7%)    4 (13%)   5 (16%)    19 (63%)

  Group 2                                 5 (16%)   4 (13%)   16 (53%)   5 (16%)

  **Ear Discharge**                                                      

  Group 1                                 0 (0%)    1 (3%)    4 (13%)    25 (83%)

  Group 2                                 0 (0%)    2 (7%)    23 (77%)   5 (16%)

  **Skin Itching**                                                       

  Group 1                                 0 (0%)    0 (0%)    1 (3%)     29

  Group 2                                 0 (0%)    1 (3%)    1 (3%)     28

  **Tragus Symptom**                                                     

  Group 1                                 0 (0%)    0 (0%)    3 (10%)    27 (90%)

  Group 2                                 0 (0%)    8 (27%)   7 (23%)    15 (50%)

  **Increase in Body Temperature**                                       

  Group 1                                 3 (10%)   3 (10%)   23 (77%)   1 (3%)

  Group 2                                 6 (20%)   6 (20%)   18 (60%)   0 (0%)

  **Otoscopy**                                                           

  **Flushing**                                                           

  Group 1                                 0 (0%)    0 (0%)    0 (0%)     30 (100%)

  Group 2                                 0 (0%)    0 (0%)    0 (0%)     30 (100%)

  **Infiltration**                                                       

  Group 1                                 0 (0%)    0 (0%)    0 (0%)     30 (100%)

  Group 2                                 0 (0%)    0 (0%)    0 (0%)     30 (100%)

  **EACO narrowing**                                                     

  Group 1                                 0 (0%)    2 (7%)    3 (10%)    25 (83%)

  Group 2                                 0 (0%)    4 (14%)   5 (16%)    21 (70%)

  **Difficult microscopic examination**                                  

  Group 1                                 0 (0%)    0 (0%)    2 (7%)     28 (94%)

  Group 2                                 0 (0%)    2 (7%)    2 (7%)     26 (87%)
  ----------------------------------------------------------------------------------

Abbreviations: AEBO, Acute External Bacterial Otitis; CEBO, Chronic External Bacterial Otitis; EACO, external auditory canal.

#### Ear Pain

On Day 1, all (100%) patients presented with severe ear pain in both the groups. Post treatment, in Group 1, on Day 3, severe ear pain persisted in 4 (13%) patients, followed by moderate and mild ear pain in 8 (27%) and 18 (60%) patients, respectively. On Day 5, only one (3%) patient had severe ear pain; 2 (6%) and 6 (20%) patients had mild and moderate pain, respectively. We observed complete resolution of symptoms in 21 (70%) patients.

In Group 2, on Day 3, severe ear pain persisted in 1 (3%) patient, followed by moderate and mild ear pain in 15 (50%) and 14 (47%) patients, respectively. On Day 5, 3 (10%) patients each had mild and moderate pain, respectively. We observed complete resolution of symptoms in 24 (80%) patients.

On Day 10, ear pain resolved completely in all the patients in both the groups except for the persistence of mild pain in 1 patient in Group 1 ( [Fig. 1](#FI0520-1){ref-type="fig"} ).

![Proportion of patients with ear pain from day 1 to day 10.](10-1055-s-0037-1598648-i0520-1){#FI0520-1}

#### Hearing Acuity

On Day 1, hearing impairment was severe in 19 (63%) patients, moderate in 5 (17%), and mild in 4 (13%) patients in Group 1. We observed further improvement on Day 3 and Day 5 with only 7 (23%) patients having severe, 10 (33%) patients having moderate, and 9 (30%) patients having mild symptoms on Day 3 and 2 (6%) patients with severe, 5 (17%) with moderate, and 2 (6%) patients with mild hearing impairment on Day 5.

However, in Group 2, on Day 1, hearing impairment was severe in 5 (16%) patients, moderate in 16 (53%), and mild in 4 (13%) patients. On Day 3, 1 (3%) patient had severe, 12 (40%) patients had moderate, and 10 (33%) patients had mild symptoms. On Day 5, moderate hearing loss persisted in 2 (6%) patients and mild in 3 (10%) patients.

By Day 10, 21% and 25% patients completely recovered in Group 1 and Group 2, respectively ( [Fig. 2](#FI0520-2){ref-type="fig"} ).

![Proportion of patients with hearing loss from day 1 to day 10.](10-1055-s-0037-1598648-i0520-2){#FI0520-2}

#### Narrowing of External Auditory Canal Opening

On Day 1, we observed severe narrowing of the opening of the external auditory canal (EACO) cartilage part in 25 (83%) patients in Group I and 21 (70%) patients in Group II, moderate in 3 (10%) patients in Group I and 5 (17%) patients in Group II, and mild in 2 (7%) patients in Group I and 4 (13%) patients in Group II.

On Day 3, severe narrowing of EACO persisted in 15 (50%) patients in Group I and 11 (37%) patients in Group II. Moderate narrowing was reported in 10 (33%) patients in Group I and 9 (30%) patients in Group II, and mild in 5 (17%) patients in Group I and in 10 (33%) patients in Group II.

Overall, the narrowing as observed by otoscopy, persisted in 12 (40%) patients and 13 (43%) patients in Group 1 and Group 2, respectively, on Day 5.

Similarly, positive dynamics and complete resolution of other signs and symptoms such as ear discharge ( [Fig. 3](#FI0520-3){ref-type="fig"} ), skin itching, tragus symptom (high tenderness while pressing tragus), increase in body temperature ( [Fig. 4](#FI0520-4){ref-type="fig"} and [Fig. 5](#FI0520-5){ref-type="fig"} ), flushing and skin infiltration, and difficult microscopic examination were also present in patients from baseline to Day 10 in both groups.

![Proportion of patients with ear discharge from day 1 to day 10.](10-1055-s-0037-1598648-i0520-3){#FI0520-3}

![Proportion of patients with body temperature from day 1 to day 10 (Acute External Bacterial Otitis).](10-1055-s-0037-1598648-i0520-4){#FI0520-4}

![Proportion of patients with body temperature from day 1 to day 10 (Chronic External Bacterial Otitis).](10-1055-s-0037-1598648-i0520-5){#FI0520-5}

### Microbial Effectiveness

In patients with AEBO (Group 1), *S. aureus* was the predominant strain, detected in 15 cases, *P. aeruginosa* in 14 cases, and *E. coli* in 1 case. In CEBO group, *S. aureus* was present in 11 patients, followed by *P. aeruginosa* and *E. coli* .

The details of Microbial Culture in both the groups pre- and post- treatment is shown in [Table 2](#TB0520-2){ref-type="table"} .

###### Microbiological characteristic of otitis externa causative agents in the examined patients

                         Group 1   Group 2            
  ---------------------- --------- --------- -------- -------
  *S. aureus*            15        −         11       1
  *P. aeruginosa*        14        −         8        −
  *E. coli*              1         −         3        −
  *Е. aerogenes*         −         −         3        −
  *S. epidermidis.*      −         3         −        5
  *Acinetobacter spp.*   −         −         2        −
  *Klebsiella spp.*      −         −         2        1
  *K. ascorbata*         −         −         1        −
  **Total**              **30**    **3**     **30**   **7**

As reported earlier, we achieved clinical success in 28 patients in the AEBO group and in 27 patients in the CEBO group, which was also confirmed by microbiological test.

On Day 10, 5 patients in Group 2 and 3 patients in Group 1 revealed the presence of *S. epidermidis* on microbial culture, which should be regarded as saprophytic flora. However, 2 patients in Group 2 revealed *S. aureus* and *Klebsiella spp* . in their microbial culture.

### Safety

It should be noted that we did not observe drug-associated adverse events and side effects in patients during the treatment.

On Day 10, Subjective general efficacy assessment was "Pronounced" and Subjective general tolerability assessment was "Good."

The percentage of patients with positive dynamics of otoscopic signs of otitis externa was 100% in both the groups by Day 10.

The percentage of patients with full resolution of the inflammatory process was 20% in Group 1 (6 patients) and 17% in Group 2 (5 patients) on Day 5, which drastically improved on Day 10 with 93% in Group 1 (28 patients) and 90% in Group 2 (27 patients) reporting complete resolution of the inflammatory process.

Discussion
==========

The empirical treatment of otitis externa utilizes the drugs with broad spectrum of activity and with a higher efficacy against common pathogens, such as *P. aeruginosa* and *S. aureus* . Fluoroquinolones have this property led by ciprofloxacin; which has a very high bactericidal activity against wide spectrum of pathogens including both gram positive and gram negative organisms with no ototoxic side effects.

We conducted the present observational study in otitis externa outpatients with an intent to study the clinical and microbiological efficacy and safety of oral ciprofloxacin prescribed to patients in the clinical settings.

A prospective observational study conducted in AEBO patients by Pabla et al observed that the majority of patients (44%) in the ENT clinic were prescribed topical antibiotics with oral antibiotics in patients with severe disease or those with high risk; only 14% were given topical treatment by their physician. This demonstrates a wide variation in the usage of topical or/and oral antibiotics in clinical practice in the management of otitis externa. [@JR0520-7]

An epidemiological survey by Rowlands et al had also shown a similar ambiguity in UK General Practice and emphasizes a dire need to develop the standard guidelines to guide clinicians for administering the appropriate treatment regimen to patients with OE. [@JR0520-8]

Although topical antimicrobial therapy is highly effective, it may at times fail due to failure of delivery and inability to reach the infection site properly. This occurs due to various reasons such as ear canal occlusion due to wax, debris, edema, and granulation tissue. In such cases, systemic antibiotics remains a better treatment option for the prescribers. Nevertheless, topical preparations are more likely to attain higher concentrations at the target site and had comparatively better cure rates than systemic antimicrobials, as studied earlier. [@JR0520-7] Thus, the best approach may be to use the combination of both systemic and topical treatment.

The first evidence based clinical practice guidelines on acute otitis externa (AOE) management was produced by the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF). The recommendations suggest that topical preparations should be used in diffuse uncomplicated AOE as compared with systemic antibiotics, which should not be routinely used and recommended only in complicated cases, such as those in which the disease extends out from the ear canal or in immuno-compromised states, among others. [@JR0520-9]

Ear syringing to remove wax, inserting foreign objects in the ear canal, or any such practices should be discouraged particularly in high risk patients prone to develop "malignant" or "invasive" otitis externa. Instead, high risk patients should be advised for early referral to the ENT department for proper assessment and treatment. [@JR0520-9]

In a study by Roland et al, results showed that Ciprofloxacin/Dexamethasone treatment resulted in greater pain relief attained over the first 3 days in patients with acute OE compared with Neomycin/Polymyxin/Hydrocortisone and a rapid reduction in severe pain after treatment initiation. [@JR0520-10]

In our study, complete resolution of the inflammatory process in the external auditory canal was observed in 28 (93%) patients in AEBO group and 27 (90%) patients in CEBO group. This was also confirmed by microbiological test. *S. aureus* and *Klebsiella spp.* were detected in the culture of two patients in CEBO group on Day 10. The lack of treatment is most likely due to the development of ciprofloxacin resistant strains.

Additionally, we observed good positive dynamics of otoscopic signs, with 100% of patients showing good results by Day 10 in both the groups.

Swimming was identified as the significant risk factor associated with the disease. However, pathogenic organisms, *S. aureus* and *P. aeruginosa* , were considered to be the most common etiology, with *S. aureus* being a dominant organism in our study. This varied slightly from the survey by Feinmesser et al, where *P. aeruginosa* was the dominant pathogen in swimmers with OE. [@JR0520-11]

Our study is conducted independent of the disease duration; we studied both acute and chronic otitis externa patients. The study results are similar to the studies done earlier.

Clinical cure and bacteriological eradication rates are comparatively better in the quinolone containing monotherapies vis a vis classic antibiotic-steroid combination drugs. This was confirmed in the meta-analysis done by Mosges et al for the first time. [@JR0520-12] They showed a significantly higher cure rate (OR: 1.29; 95% CI: 1.06--1.57; *p*  = 0.01) and a significantly superior eradication rate (OR: 1.44; 95% CI: 1.03--2.02; *p*  = 0.03) by the use of quinolone drugs.

Dosing schedules of systemic administration have not been studied; topical therapy (quinolone drops) suggests twice daily dosing. In an open label study, ofloxacin showed good clinical outcomes with once daily regimen. The optimal duration of therapy varies from a few days to several weeks in published studies. [@JR0520-9] Our study demonstrated the effectiveness of twice daily dosing of oral ciprofloxacin for 7 to 10 days.

The well-defined regimens of the marketed products have clear advantages, such as less frequent dosing and shorter duration of therapy; this further improves patient\'s compliance, reducing the development of bacterial resistance and the potential for unwanted side effects.

During the monitoring of AEBO and exacerbation of CEBO treatment, no adverse events associated with the drug products were reported.

A further study with larger sample size is warranted to draw any firm conclusion.

Conclusion
==========

We found Ciprofloxacin (1000 mg daily for 7 to 10 days) to be an effective and safe drug for the treatment of otitis externa; it is a prudent in clinical practice and may be prescribed on routine basis, especially in severe cases or in high risk patients suffering from diabetes or immune suppression.

This trial is registered with <http://clinicaltrials.gov> , number NCT02140073.
